RecruitingNCT04411225
Study of cannabidiol added to usual care in early psychosis
About this title
Read the official source — NCT04411225Medication studyAges 16–30United StatesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 16 years to 30 years.
- Listed locations
- La Jolla and 1 more locationSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 1, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- University of California, San Diego
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 16 Years to 30 Years
- Official registry ID
- NCT04411225
- Official title
Show the full official title
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis: Understanding the Mechanism and Mediators of Action
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
La Jolla · San Diego
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of California, San Diego, a university.
Does this study involve medication?
Yes. The study involves medication, including Cannabidiol oral solution.
Who can participate?
Listed age limits: 16 years to 30 years.
Is this study still recruiting?
The registry lists this study as recruiting.
